Renal cancer

  1. A phase III, randomized, double-blind, placebo-controlled clinical trial of pembrolizumab (MK-3475) as monotherapy in the adjuvant treatment of renal cell carcinoma post nephrectomy (KEYNOTE-564)
    The purpose of the study is to assess the tolerability and effectiveness of the adjuvant therapy drug pembrolizumab (MK-3475) in patients who have renal cancer and for whom other therapies are not administered following a partial or complete tumor removal surgery.
    Primary researcher: Katriina Peltola

  2. A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
    The purpose of the study is to conduct comparison of two different starting doses of lenvatinib in the trial drug combination (lenvatinib and everolimus) in treatment of renal cancer.
    Primary researcher: Petteri Hervonen

 COntact information
tel. +358 50 427 0680